Protagonist Therapeutics (PTGX) IPO Opened Flat

Today's IPO for Protagonist Therapeutics (NASDAQ: PTGX) opened for trading earlier at $12 after pricing 7,500,000 shares of common stock at a price to the public of $12 per share, the middle of the expected $11 - $13 range.

Leerink Partners LLC, Barclays Capital Inc. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs.

You May Also Be Interested In

• Scribe Therapeutics files for proposed Nasdaq IPO
• Bending Spoons closes IPO, raises ~$954M on Nasdaq
• Viking Acquisition Corp II (VACI) Opens at $10.04, IPO was priced at $10